Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.66)
# 3,838
Out of 4,944 analysts
32
Total ratings
24%
Success rate
-18.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $10.57 | +183.82% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $38.49 | +55.88% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $11.11 | +125.02% | 3 | Jun 23, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $10.01 | +199.70% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $20.19 | +63.45% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $3.09 | +158.90% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $24.42 | +104.75% | 2 | Feb 14, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $7.35 | +104.08% | 2 | Jan 22, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $40.74 | +47.28% | 2 | Jan 21, 2025 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.60 | +212.50% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $2.33 | +71.67% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.09 | +675.74% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.07 | +1,114.95% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $7.56 | +1,222.79% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.70 | +1,076.47% | 1 | May 14, 2024 |
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $10.57
Upside: +183.82%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $38.49
Upside: +55.88%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $11.11
Upside: +125.02%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $10.01
Upside: +199.70%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $20.19
Upside: +63.45%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.09
Upside: +158.90%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $24.42
Upside: +104.75%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.35
Upside: +104.08%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $40.74
Upside: +47.28%
Actinium Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.60
Upside: +212.50%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $2.33
Upside: +71.67%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.09
Upside: +675.74%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.07
Upside: +1,114.95%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $7.56
Upside: +1,222.79%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.70
Upside: +1,076.47%